Ventyx Biosciences (NASDAQ:VTYX) Earns “Neutral” Rating from HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “neutral” rating restated by HC Wainwright in a report issued on Tuesday,Benzinga reports.

Separately, Oppenheimer restated an “outperform” rating and issued a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Stock Up 0.5 %

NASDAQ VTYX traded up $0.01 on Tuesday, hitting $1.96. The stock had a trading volume of 554,183 shares, compared to its average volume of 2,130,565. Ventyx Biosciences has a one year low of $1.67 and a one year high of $11.48. The stock has a market cap of $138.59 million, a price-to-earnings ratio of -0.83 and a beta of 0.55. The company’s 50-day moving average is $2.29 and its two-hundred day moving average is $2.28.

Insider Activity

In other news, CEO Raju Mohan purchased 261,752 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the transaction, the chief executive officer now owns 2,175,028 shares in the company, valued at $4,371,806.28. The trade was a 13.68 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John Nuss sold 13,161 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the completion of the sale, the insider now owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased 630,000 shares of company stock worth $1,262,415 over the last three months. Corporate insiders own 18.18% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C increased its stake in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after purchasing an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC increased its stake in shares of Ventyx Biosciences by 153.2% during the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after purchasing an additional 1,193,024 shares during the last quarter. Vestal Point Capital LP grew its stake in Ventyx Biosciences by 31.2% in the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after buying an additional 410,000 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Ventyx Biosciences in the 2nd quarter valued at $608,000. Finally, XTX Topco Ltd acquired a new position in Ventyx Biosciences in the 3rd quarter valued at $246,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.